Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Celldex TherapeuticsCLDX -3.31%56 Cash-to-Debt is 146.33 as of Jun. 2026, which is 6% below its 10-year median of 156.48. GuruFocus rates CLDX with a GF Score™ of 56/100 and a GF Value™ of $2.43 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,355 Biotechnology companies, Celldex Therapeutics ranks better than 78.52% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Celldex Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 146.33.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Celldex Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Celldex Therapeutics's Cash-to-Debt or its related term are showing as below:
CLDX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 14.18 Med: 156.48 Max: No Debt
Current: 146.33
During the past 13 years, Celldex Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 14.18. And the median was 156.48.
CLDX's Cash-to-Debt is ranked better than 78.52% of 1355
companies
in the Biotechnology industry
Industry Median: 7.29
vs CLDX: 146.33
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Celldex Therapeutics Cash-to-Debt Related Terms
Celldex Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Celldex Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Celldex Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celldex Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Celldex Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celldex Therapeutics (CLDX) has a Cash-to-Debt of 146.33 as of Jun. 2026. This is near median its historical median of 156.48. Over the past decade, Celldex Therapeutics' Cash-to-Debt has ranged from 14.18 to 10,000.00. According to the industry distribution chart, Celldex Therapeutics ranks #291 out of 1355 companies in the Biotechnology industry, placing it in the top 21.5%.
Is Celldex Therapeutics' Cash-to-Debt too high?
Celldex Therapeutics' current Cash-to-Debt of 146.33 is near median its 10-year median of 156.48. Over the past 10 years, this metric has ranged from a low of 14.18 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.29. Celldex Therapeutics' value of 146.33 is 1907.3% above this industry median. Based on the distribution chart, Celldex Therapeutics ranks #291 out of 1355 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Celldex Therapeutics has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' Cash-to-Debt compare to IRON and QURE?
According to the Biotechnology industry distribution chart, Celldex Therapeutics ranks #291 out of 1355 companies for Cash-to-Debt. This places Celldex Therapeutics in the top 22% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 7.29. Celldex Therapeutics' value of 146.33 is 1907.3% above this benchmark. Historically, Celldex Therapeutics' own Cash-to-Debt has ranged from 14.18 to 10,000.00 over the past decade. While the company's 10-year median is 156.48 vs. the industry median of 7.29, Celldex Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.29, based on 1,355 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celldex Therapeutics's current Cash-to-Debt of 146.33 is 1907.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celldex Therapeutics's current Cash-to-Debt is 146.33, which is near median its own 10-year median of 156.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (CLDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.43, compared to a current price of $39.10 — trading 1509.1% above its estimated fair value. The current Cash-to-Debt is 146.33, which is near median its 10-year median of 156.48 and 1907.3% above the Biotechnology industry median of 7.29. Celldex Therapeutics' overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Celldex Therapeutics (CLDX), the current Cash-to-Debt is 146.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celldex Therapeutics (CLDX) Overvalued in 2026?
Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued.
The current stock price of $39.10 is trading 1509.1% above its estimated GF Value™ of $2.43.
GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.
Key valuation signals for CLDX:
Cash-to-Debt: 146.33 (near median its 10-year median of 156.48)
GF Value™: $2.43 vs. price of $39.10 (1509.1% above fair value)
Industry Position: 1907.3% above the Biotechnology median (#291 of 1355)
No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
56GF Score
Get the complete analysis for CLDX
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLDX has been successfully added to your 
